Page 1038 of 1,038: studies 10,371 to 10,380 of 10,380, newest first. Back to the depression overview
Milind Raskar
Soma, the sacred plant of the Rigveda, and its Iranian counterpart Haoma in the Avesta, have long remained shrouded in mystery. While earlier scholarship identified Soma with various candidates such as Amanita muscaria, Ephedra, Cannabis, and Peganum harmala, no consensus has emerged. This study offers a multidisciplinary approach, combining textual analysis, fieldwork in the Kutch region of...
Anja Frank, Mario H W Scheib preprint
Introduction: Europe faces a worsening mental health crisis, with nearly half of the population (46%) reporting emotional or psychological issues, such as depression, within the last year. One in six Europeans is currently affected by mental health problems, equating to approximately 84 million individuals across the continent (Nawrocka, 2023). Method: This study examines the impact of a...
Viviana D. Evans, Alejandro Arenas, Kenneth Shinozuka et al. preprint
Background: Ketamine, an arylcyclohexylamine dissociative anesthetic agent, has evolved into a versatile therapeutic. It has a rapid onset, well-understood cardiovascular effects, and a favorable safety profile in clinical use. Its enantiomeric compound, esketamine, was approved by the FDA in 2019 for both treatment-resistant depression as well as major depressive disorder (MDD) with suicidal...
Meghan Good, Tiffanie Benway, Zelah Joel et al. 4 citations
Aim: N,N-dimethyltryptamine (DMT) is a psychedelic compound under development for the treatment of major depressive disorder (MDD). This study evaluated the in vitro metabolism and clinical pharmacokinetics (PK) of DMT fumarate (SPL026) in healthy subjects. Methods: Results are from the Phase I component of an ongoing Phase I/IIa randomised, double-blind, placebo-controlled, parallel-group,...
Gregory preprint
This paper presents a critical re-examination of the conclusions drawn from Szigeti et al.'s (2021) “Self-blinding Citizen Science to Explore Psychedelic Microdosing”. The current article’s approach was to a) examine the utility of the guess and expectation variables from the original research, b) explore if drug intensity plays a role in the outcomes, and c) test for within-person variability...
Bryce D. Beutler, Kenneth Shinozuka, Burton J. Tabaac et al. preprint
Background: Lysergic acid diethylamide (LSD) is a hallucinogenic agent. In the mid-20th century, it was used to augment psychoanalysis and to treat alcohol use disorder. However, LSD was banned in 1970 in part due to concerns that it could bring about or exacerbate mental illness. Its therapeutic potential remains incompletely understood.Areas of Uncertainty: While uncontrolled recreational use...
Burton J. Tabaac, Kenneth Shinozuka, Anne Weisman et al. preprint
Background: 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), also officially known as Mebufotenin, is a naturally occurring serotonergic psychedelic alkaloid found in the venom of the Sonoran Desert toad (Incilius alvarius) and various plant species. Areas of Uncertainty: Trace levels of 5-MeO-DMT may be produced endogenously in humans, but its physiological role remains unclear. Safety profiles...
Kenneth Shinozuka, Burton J. Tabaac, Alejandro Arenas et al. preprint
Background: N,N-dimethyltryptamine (DMT) is a naturally-occurring serotonergic psychedelic found in natural plants around the globe. As the main psychoactive component in ayahuasca, which also contains monoamine oxidase (MAO) inhibitors, DMT has been consumed as plant-based brew by indigenous peoples for centuries. Further research is required to delineate the therapeutic utility of DMT.Areas...
Joe Hardy, Hannes Kettner, David R. Glowacki et al. preprint
Introduction. Being diagnosed with a life-threatening illness (LTI) is often accompanied by feelings of fear, uncertainty, and loneliness that can severely impact mental health. Relatively few interventions are available to address the existential concerns of individuals facing LTI, while treatment of the underlying physical ailment typically remains the priority of the healthcare system....
bioRxiv (Cold Spring Harbor Laboratory) Hanna M. Tolle, Andrea I. Luppi, Timothy Lawn et al. 1 citation preprint
Conventional antidepressants show moderate efficacy in treating major depressive disorder. Psychedelic-assisted therapy holds promise, yet individual responses vary, underscoring the need for predictive tools to guide treatment selection. Here, we present graphTRIP (graph-based Treatment Response Interpretability and Prediction) – a geometric deep learning architecture that enables three...